AMENDMENT NO. 1 TO COMMERCIAL DEVELOPMENT AND SUPPLY AGREEMENT and LICENSE AGREEMENTCommercial Development and Supply Agreement and License Agreement • February 27th, 2020 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
This Amendment No. 1 to Commercial Development and Supply Agreement (“Amendment No. 1”) effective as of 18 November, 2019 (“Amendment No. 1 Effective Date”) is entered into by and between ADAPTIMMUNE Limited, with offices at 60 Jubilee Avenue (formerly 101 Park Drive), Milton Park, Abingdon, Oxon, OX14 4RX, England (“ADAPTIMMUNE”) and Life Technologies Corporation, an Affiliate of Thermo Fisher Scientific Inc., with offices at 5781 Van Allen Way (formerly 5791), Carlsbad, California 92008 (“LIFE”). and amends the Commercial Development and Supply Agreement effective as of June 1, 2016 entered into by ADAPTIMMUNE and LIFE (“Supply Agreement”). ADAPTIMMUNE and LIFE each hereinafter a “Party” and collectively “Parties”.
